Aldeyra Therapeutics, Inc. announced positive top-line results from the Phase 2 clinical trial of orally administered ADX--629, an investigational new drug, in patients with chronic cough. The clinical trial demonstrated statistically significant reduction in cough frequency following administration of ADX--629 relative to placebo.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.205 USD | +2.81% | +14.05% | +20.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.23% | 243M | |
+18.26% | 123B | |
+15.00% | 107B | |
-4.12% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.03% | 16.23B | |
+2.80% | 13.43B | |
+26.78% | 11.32B |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough